缬沙坦治疗早期肥厚型心肌病:一项随机2期试验
本研究为多中心、双盲、安慰剂对照2期试验,纳入178例早期肌节性肥厚型心肌病(HCM)患者,按1:1随机接受缬沙坦或安慰剂治疗2年。主要终点为心脏结构、功能及生物标志物变化的复合z评分。缬沙坦组复合z评分较安慰剂组提高(组间差+0.231,95%CI +0.098至+0.364,P=0.001),达到主要终点,且治疗耐受性良好。
要点
- 缬沙坦可改善早期肌节性HCM患者的心脏结构和功能复合评分。
- 组间复合z评分差异为+0.231(95%CI +0.098至+0.364,P=0.001)。
- 缬沙坦在早期HCM中耐受性良好。
核心结论
- 缬沙坦治疗2年可改善早期肌节性HCM患者的心脏结构和功能复合评分,达到主要终点,且耐受性良好。
研究设计与样本
- 多中心、双盲、安慰剂对照2期临床试验,纳入178例早期肌节性HCM患者,按1:1随机分配接受缬沙坦或安慰剂治疗2年。
主要发现
- 缬沙坦组(n=88)较安慰剂组(n=90)复合z评分增加,组间差+0.231(95%CI +0.098至+0.364),P=0.001。
- 治疗耐受性良好。
关键数值与推荐
- 主要终点为左室壁厚度、质量、容积、左房容积、组织多普勒舒张和收缩速度、高敏肌钙蛋白T和NT-proBNP从基线至2年的标准化变化整合而成的复合z评分。
- 缬沙坦剂量为成人每日320 mg,儿童每日80-160 mg。
临床怎么用
- 对于早期肌节性HCM患者,缬沙坦可能作为延缓疾病进展的安全且可及的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and increased risk of heart failure and arrhythmias. There are no existing therapies to modify disease progression. In this study, we conducted a multi-center, double-blind, placebo-controlled phase 2 clinical trial to assess the safety and efficacy of the angiotensin II receptor blocker valsartan in attenuating disease evolution in early HCM. In total, 178 participants with early-stage sarcomeric HCM were randomized (1:1) to receive valsartan (320 mg daily in adults; 80-160 mg daily in children) or placebo for 2 years ( NCT01912534 ). Standardized changes from baseline to year 2 in LV wall thickness, mass and volumes; left atrial volume; tissue Doppler diastolic and systolic velocities; and serum levels of high-sensitivity troponin T and N-terminal pro-B-type natriuretic protein were integrated into a single composite z-score as the primary outcome. Valsartan (n = 88) improved cardiac structure and function compared to placebo (n = 90), as reflected by an increase in the composite z-score (between-group difference +0.231, 95% confidence interval (+0.098, +0.364); P = 0.001), which met the primary endpoint of the study. Treatment was well-tolerated. These results indicate a key opportunity to attenuate disease progression in early-stage sarcomeric HCM with an accessible and safe medication.
引用
- Ho CY, Day SM, Axelsson A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021. PMID: 34556856. doi:10.1038/s41591-021-01505-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。